High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

2009820 citationsJournal Articlebronze Open Access

Authors

Bob Löwenberg · Erasmus MC

Gert J. Ossenkoppele · University Medical Center

Wim van Putten · Erasmus MC

Harry C. Schouten · University Medical Center

Carlos Graux · Institut du Savoir Montfort

Augustin Ferrant · Hôpital Saint-Luc

Pieter Sonneveld ·

Abstract

In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional dose, without additional toxic effects. (Current Controlled Trials number, ISRCTN77039377; and Netherlands National Trial Register number, NTR212.)

Topics & Keywords

Acute Myeloid Leukemia Research Retinoids in leukemia and cellular processes Multiple Myeloma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 361, Issue 13, pp. 1235-1248

DOI: 10.1056/nejmoa0901409

Field-Weighted Citation Impact: 29.23